Preventing relapse of advanced ovarian cancer with PARP inhibitors is now an established strategy. As data from pivotal ...
The median follow-up of 37 months showed that PSMAiSRT improved FFS and eugonadal FFS, with significant improvements in the ...
Patients in the no LND arm had shorter surgery duration, less blood loss, and reduced postoperative hospital stay compared to ...
The FDA has granted fast track designation to the investigational therapeutic agent WTX-124 for the potential treatment of ...
Cemiplimab significantly improved disease-free survival in high-risk CSCC, reducing recurrence or death risk by 68% compared ...
A new study explores strategies to enhance survival rates for patients facing challenges in finding bone marrow donors, advocating for quicker alternative options. Stephanie Lee, MD, MPH, professor ...
The FDA has issued a complete response letter (CRL) to a new drug application (NDA) for Dasynoc for the treatment of chronic ...
Casdatifan activates hundreds of genes in response to low oxygen levels, and when oxygen levels return to normal, HIF-2a is ...
During a live event, Claudine Isaacs, MD, discussed using elacestrant for hormone receptor–positive, HER2-low metastatic ...
Cintredekin besudotox targets IL-12 alpha-2 receptor-expressing tumor cells, using convection-enhanced delivery to bypass the ...
NBTXR3 combined with radiotherapy and ICIs showed a 47.4% objective response rate and 78.9% disease control rate in melanoma ...
Active surveillance (AS) appears to be a durable and safe long-term management strategy for patients with small, low-risk papillary thyroid cancer (PTC), with durability and age strongly correlated, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback